The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Open accessAbstract
Introduction: Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid‐binding positron emission tomography studies, are limited by cost and availability. There is a need for a more practical amyloid β (Aβ) biomarker for central nervous system amyloid deposition. Methods: We adapted our previously reported stable isotope labeling kinetics protocol to analyze the turnover kinetics and concentrations of Aβ38, Aβ40, and Aβ42 in human plasma. Results: Aβ isoforms have a half‐life of approximately 3 hours in plasma. Aβ38 demonstrated faster turnover kinetics compared with Aβ40 and Aβ42. Faster fractional turnover of Aβ42 relative to Aβ40 and lower Aβ42 and Aβ42/Aβ40 concentrations in amyloid‐positive participants were observed. Discussion: Blood plasma Aβ42 shows similar amyloid‐associated alterations as we have previously reported in cerebrospinal fluid, suggesting a blood‐brain transportation mechanism of Aβ. The stability and sensitivity of plasma Aβ measurements suggest this may be a useful screening test for central nervous system amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“an 8-year follow-up study of 599 volunteers (average age 70 years) in Australia found that cognitively normal PET amyloid-positive people had an elevated risk of developing Alzheimer's disease compared with amyloid negative (17·7% vs 8·1%; OR 2·4, 95% CI 1·5–4·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma Aβ measures now show promise [202,203].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The cited source says what the claim attributes to it.
In the citing paper
“While imaging/CSF biomarker data on subsets of individuals from well-designed community-based cohorts would provide additional research value, incorporating biomarkers on a large scale in many settings will require low-cost and minimally invasive biomarkers (e.g., blood or saliva) that are now emerging [202–205].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Over 80% of the 266 people who were PET amyloid-positive did not go onto develop a cognitive impairment within 8 years, showing positive status does not predict impairment for most people in a timeframe that might be a useful prognostic window.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Follow-up at 5 years of amyloid-positive participants with normal cognition or mild cognitive impairment versus amyloid negative people found the same pattern of increased risk (2·6, 1·4–4·9).”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Risk also increases per 1 year of age (HR 1·05, 95% CI 0·55–2·0/year), and APOEε4 status (2·6, 1·4–5·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredIn the citing paper
“Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking, although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in the blood have been reported5–10.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [8]
In the citing paper
“Recent studies demonstrate the ability to detect CNS Aβ deposition via the use of plasma assessment of Aβ species”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Ovod et al., 2017
In the citing paper
“Most recently, 2 independent groups demonstrated improved accuracy for plasma Aβ42/Aβ40 using immunoprecipitation–mass spectrometry assays.19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
In the citing paper
“In mass spectrometry–based techniques, 2 recent studies have provided overall better accuracies for plasma Aβ42/Aβ40 (AUC, 0.84-0.97 depending on population and reference standard).19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“3%, respectively, when confirmed by postmortem histopathology [4].”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Self-citationAge but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258
Cited by
Sorted by citations
Items 201–300 of 586
Jang, H., Kim, J. S., Lee, H. J., Kim, C., Na, D. L., Kim, H. J., Allué, J. A., Sarasa, L., Castillo, S., Pesini, P., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00911-7 · Cited by 36
Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention
Udeh‐Momoh, C. T., Zheng, B., Matton, A., Novak, G., Kivipelto, M., Jönsson, L., & Middleton, L. T. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.70 · Cited by 38
Alzheimer’s Disease Clinical Trials: Moving Toward Successful Prevention
Rafii, M. S., & Aisen, P. S. (2019) · CNS Drugs · doi:10.1007/s40263-018-0598-1 · Cited by 36
Westwood, S., Baird, A. L., Hye, A., Ashton, N. J., Nevado‐Holgado, A. J., Anand, S. N., Liu, B., Newby, D., Bazenet, C. E., Kiddle, S. J., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00409 · Cited by 35
Chen, T., Lai, Y.-H., Ke, T.-L., Chen, J.-P., Lee, Y.-J., Lin, S.-Y., Lin, P.-C., Wang, P., & Cheng, I. H.-J. (2019) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000505435 · Cited by 36
ADNI Biomarker Core: A review of progress since 2004 and future challenges
Shaw, L. M. J., Korecka, M., Lee, E. B., Cousins, K. A. Q., Vanderstichele, H., Schindler, S. E., Tosun, D., DeMarco, M. L., Brylska, M., Wan, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14264 · Cited by 38
Blood-based biomarkers in Alzheimer’s disease: a mini-review
Padala, S. P., & NEWHOUSE, P. A. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01114-1 · Cited by 39
Kononikhin, A. S., Zakharova, N. V., Semenov, S. D., Bugrova, A. E., Brzhozovskiy, A. G., Indeykina, M. I., Fedorova, Y. B., Колыхалов, И. В., Strelnikova, P. A., Ikonnikova, A. Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147907 · Cited by 33
Chatterjee, P., Doré, V., Pedrini, S., Krishnadas, N., Thota, R. N., Bourgeat, P., Ikonomović, M. D., Rainey‐Smith, S. R., Burnham, S. C., Fowler, C. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220908 · Cited by 36
Zeng, X., Sehrawat, A., Lafferty, T. K., Chen, Y., Rawat, M., Kamboh, M. I., Villemagne, V. L., López, O. L., Cohen, A. D., & Karikari, T. K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14535 · Cited by 33
Vogelgsang, J. S., Shahpasand‐Kroner, H., Vogelgsang, R., Streit, F., Vukovich, R., & Wiltfang, J. (2018) · Experimental Brain Research · doi:10.1007/s00221-018-5210-x · Cited by 34
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain
Burnham, S. C., Fandos, N., Fowler, C. J., Pérez‐Grijalba, V., Doré, V., Doecke, J. D., Shishegar, R., Cox, T. O., Fripp, J., Rowe, C. C., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa041 · Cited by 32
Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study
Pomara, N., Bruno, D., Plaska, C. R., Ramos‐Cejudo, J., Osorio, R. S., Pillai, A., Imbimbo, B. P., Zetterberg, H., & Blennow, K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02077-8 · Cited by 38
A critical appraisal of blood-based biomarkers for Alzheimer’s disease
Lista, S., Mapstone, M. E., Caraci, F., Emanuele, E., López‐Ortiz, S., Martín-Hernández, J., Triaca, V., Imbimbo, C., Gabelle, A., Mielke, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102290 · Cited by 30
Albani, D., Marizzoni, M., Ferrari, C., Fusco, F., Boeri, L., Raimondi, I., Jovicich, J., Babiloni, C., Soricelli, A., Lizio, R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180321 · Cited by 31
Tan, R., Wang, Y., Mi, X., Li, H., & Tu, Y. (2021) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2021.131065 · Cited by 31
Yan, Y., Aierken, A., Wang, C., Song, D. F., Ni, J., Wang, Z., Quan, Z., & Qing, H. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.009 · Cited by 32
Fluid Biomarkers in Dementia Diagnosis
Schindler, S. E. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001083 · Cited by 31
Schilling, L. P., Balthazar, M. L. F., Radanovic, M., Forlenza, O. V., Silagi, M. L., Smid, J., Barbosa, B. J. A. P., Frota, N. A. F., de Souza, L. C., Vale, F. A. C., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s102pt · Cited by 59
Wildburger, N. C., Gyngard, F., Guillermier, C., Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Schneider, T., Green, K., Roth, R. A., Schmidt, R. E., et al. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00169 · Cited by 32
Self-citationCai, Y. Q., Shi, D., Lan, G., Chen, L., Jiang, Y., Zhou, L., Guo, T., & Initiative, A. D. N. (2024) · Neurology · doi:10.1212/wnl.0000000000209205 · Cited by 31
Mielke, M. M., Evans, J. K., Neiberg, R. H., Molina‐Henry, D. P., Marcovina, S. M., Johnson, K., Carmichael, O. T., Rapp, S. R., Sachs, B. C., Ding, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.58149 · Cited by 31
Hirtz, C., Busto, G. U., Bennys, K., Kindermans, J., Navucet, S., Tiers, L., Lista, S., Vialaret, J., Gutierrez, L., Dauvilliers, Y. A., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01188-8 · Cited by 30
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
Wisch, J. K., Gordon, B. A., Boerwinkle, A. H., Luckett, P. H., Bollinger, J. G., Ovod, V., Li, Y., Henson, R. L., West, T., Meyer, M. R., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12405 · Cited by 35
Self-citationLv, Y., Zhou, Y., Dong, H. Y., Xu, M., Zhang, J., & Yan, M. (2023) · Talanta · doi:10.1016/j.talanta.2023.125134 · Cited by 29
Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 37
Aging and APOE ‐ε4 are determinative factors of plasma A β 42 levels
Nakamura, T., Kawarabayashi, T., Seino, Y., Hirohata, M., Nakahata, N., Narita, S., Itoh, K., Nakaji, S., & Shoji, M. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.635 · Cited by 31
In vivo Detection of Alzheimer's Disease.
Leuzy, A., Heurling, K., Ashton, N. J., Schöll, M., & Zimmer, E. R. (2018) · Europe PMC (PubMed Central) · Cited by 29
Chiu, M., Lue, L., Sabbagh, M. N., Chen, T., Chen, H. H., & Yang, S. (2019) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000496099 · Cited by 29
Biomarkers in Alzheimer’s disease
Janeiro, M. H., Ardanaz, C. G., Sola-Sevilla, N., Dong, J., Cortés-Erice, M., Solas, M., Puerta, E., & Ramírez, M. J. (2020) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2020-0090 · Cited by 37
The blood biomarkers puzzle – A review of protein biomarkers in neurodegenerative diseases
Barro, C., & Zetterberg, H. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109281 · Cited by 30
Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life
Sullivan, K., Blackshear, C. T., Simino, J. M., Tin, A., Walker, K. A., Sharrett, A. R., Younkin, S. G., Gottesman, R. F., Mielke, M. M., Knopman, D. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012482 · Cited by 29
Lue, L., Kuo, Y., & Sabbagh, M. N. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00167-2 · Cited by 29
In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer’s disease
Toombs, J., & Zetterberg, H. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa054 · Cited by 30
Oosthoek, M., Vermunt, L., de Wilde, A., Bongers, B., Antwi‐Berko, D., Scheltens, P., van Bokhoven, P., Vijverberg, E. G. B., & Teunissen, C. E. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01456-1 · Cited by 36
Zhang, Y., Bi, K., Zhou, L., Wang, J., Huang, L., Sun, Y., Peng, G., & Wu, W. (2024) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s471174 · Cited by 30
Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease.
Yun, S.-M., Cho, S.-J., Jo, C., Park, M.-H., Han, C.-S., & Koh, Y. (2019) · Archives of gerontology and geriatrics (Print) · doi:10.1016/j.archger.2019.103995 · Cited by 20
Muir, R. T., Ismail, Z., Black, S. E., & Smith, E. E. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13510 · Cited by 27
Dong, Y., Song, X., Wang, X., Wang, S., & He, Z. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70060 · Cited by 34
Shim, J.-E., Kim, Y. J., Hahm, E., Choe, J., Baek, A., Kim, R. M., & You, E. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117216 · Cited by 29
Kubota, M., Bun, S., Takahata, K., Kurose, S., Momota, Y., Iwabuchi, Y., Tezuka, T., Tabuchi, H., Seki, M., Yamamoto, Y., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01778-8 · Cited by 34
D’Andrea, C., Cazzaniga, F. A., Bistaffa, E., Barucci, A., de Angelis, M., Banchelli, M., Farnesi, E., Polykretis, P., Marzi, C., Indaco, A., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00367-9 · Cited by 27
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 28
Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta‐analyses
Alhajraf, F., Ness, D., Hye, A., & Strydom, A. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22715 · Cited by 27
Lin, S.-Y., Lin, K., Lin, P.-C., Huang, C.-C., Chang, C., Lee, Y., Hsiao, I., Yen, T., Huang, W.-S., Yang, B., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0566-0 · Cited by 26
Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach
Prete, E. D., Beatino, M. F., Campese, N., Giampietri, L., Siciliano, G., Ceravolo, R., & Baldacci, F. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040221 · Cited by 29
He, L., Barreto, P. D. S., Giudici, K. V., Aggarwal, G., Nguyen, A. D., Morley, J. E., Li, Y., Bateman, R. J., Vellas, B. J., for the MAPT/DSA Group, et al. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa284 · Cited by 26
Self-citationSchilling, L. P., Balthazar, M. L. F., Radanovic, M., Forlenza, O. V., Silagi, M. L., Smid, J., Barbosa, B. J. A. P., Frota, N. A. F., de Souza, L. C., Vale, F. A. C., et al. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2022-s102en · Cited by 29
Independent study demonstrates amyloid probability score accurately indicates amyloid pathology
Fogelman, I., West, T., Braunstein, J. B., Verghese, P. B., Kirmess, K. M., Meyer, M. R., Contois, J. H., Shobin, E., Ferber, K. L., Gagnon, J., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51763 · Cited by 25
Self-citationBlood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease
Hampel, H. J., Vergallo, A., Afshar, M., Akman-Anderson, L., Arenas, J., Benda, N., Batrla, R., Broich, K., Caraci, F., Cuello, A. C., et al. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.2/hhampel · Cited by 27
Shi, D., Xie, S., Li, A., Wang, Q., Guo, H., Han, Y., Xu, H., Gan, W., Zhang, L., Guo, T., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01899-w · Cited by 25
Sandberg, A., Berenjeno‐Correa, E., Rodriguez, R. C., Axenhus, M., Weiss, S. S., Batenburg, K. L., Hoozemans, J. J. M., Tjernberg, L. O., & Scheper, W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01141-1 · Cited by 29
Klafki, H., Rieper, P., Matzen, A., Zampar, S., Wirths, O., Vogelgsang, J. S., Osterloh, D., Rohdenburg, L., Oberstein, T. J., Jahn, O., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186564 · Cited by 24
Iino, T., Watanabe, S., Yamashita, K., Tamada, E., Hasegawa, T., Irino, Y., Iwanaga, S., Harada, A., Noda, K., Suto, K., et al. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa225 · Cited by 23
Novel Trends in Electrochemical Biosensors for Early Diagnosis of Alzheimer’s Disease
Valkova, P., & Pohanka, M. (2021) · International Journal of Analytical Chemistry · doi:10.1155/2021/9984876 · Cited by 24
Plasma MCP-1 and changes on cognitive function in community-dwelling older adults
Sánchez‐Sánchez, J. L., Giudici, K. V., Guyonnet, S., Delrieu, J., Li, Y., Bateman, R. J., Parini, A., Vellas, B. J., Barreto, P. D. S., for the MAPT/DSA Group, et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00940-2 · Cited by 25
Self-citationN-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
Rostagno, A. A., Cabrera, E., Lashley, T., & Ghiso, J. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00303-3 · Cited by 23
Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer's disease
Yu, X., Shao, K., Wan, K., Li, T., Li, Y., Zhu, X., & Han, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002566 · Cited by 23
Andersson, E., Schultz, N., Saito, T., Saido, T. C., Blennow, K., Gouras, G. K., Zetterberg, H., & Hansson, O. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01196-8 · Cited by 26
Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation
Eide, P. K., Lashkarivand, A., Pripp, A. H., Valnes, L. M., Hovd, M. H., Ringstad, G. A., Blennow, K., & Zetterberg, H. (2023) · Brain Communications · doi:10.1093/braincomms/fcad343 · Cited by 27
Wang, J., Qiao, F., Shang, S., Li, P., Chen, C., Dang, L., Jiang, Y., Huo, K., Deng, M., Wang, J., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180140 · Cited by 25
Prediction of Cerebral Amyloid With Common Information Obtained From Memory Clinic Practice
Lee, J. H., Byun, M. S., Yi, D., Sohn, B. K., Jeon, S. Y., Lee, Y., Lee, J., Kim, Y. K., Lee, Y., & Lee, D. Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00309 · Cited by 24
Present and Future of Blood-Based Biomarkers of Alzheimer’s Disease: Beyond the Classics
Grigoli, M. M., Pelegrini, L. N. D. C., Whelan, R., & Cominetti, M. R. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148812 · Cited by 22
Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease
Thijssen, E. H., & Rabinovici, G. D. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4200 · Cited by 23
Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
Klafki, H., Morgado, B., Wirths, O., Jahn, O., Bauer, C., Esselmann, H., Schuchhardt, J., & Wiltfang, J. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00390-4 · Cited by 25
Neuropsychiatric symptoms in Alzheimer's continuum and their association with plasma biomarkers
Huang, L., Huang, Q., Xie, F., & Guo, Q. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.062 · Cited by 23
Divergent Associations of Slow‐Wave Sleep versus Rapid Eye Movement Sleep with Plasma Amyloid‐Beta
Rosenblum, Y., Pereira, M., Stange, O., Weber, F. D., Bovy, L., Tzioridou, S., Lancini, E., Neville, D. A., Klein, N., de Wolff, T., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26935 · Cited by 28
Diffusion MRI relates to plasma Aβ42/40 in PET negative participants without dementia
DeSimone, J. C., Wang, W., Loewenstein, D., Duara, R., Smith, G. E., McFarland, K. N., Armstrong, M. J., Weber, D. M., Barker, W., Coombes, S. A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13693 · Cited by 22
Liquid chromatography-tandem mass spectrometry in clinical laboratory protein measurement
Ma, Y., Wang, D., Li, H., Ma, X., Zou, Y., Mu, D., Yu, S., Cheng, X., & Qiu, L. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119846 · Cited by 22
Pre-Analytical Sampling and Storage Conditions of Amyloid-β Peptides in Venous and Capillary Blood
Walter, M., Wiltfang, J., & Vogelgsang, J. S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200777 · Cited by 22
Mehta, P. D., Patrick, B. A., Miller, D. L., Coyle, P. K., & Wısnıewskı, T. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200861 · Cited by 22
Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity
Pyun, J., Ryu, J. S., Lee, R. Y., Shim, K., Youn, Y. C., Ryoo, N., Han, S., Park, Y. H., Kang, S., An, S. S. A., et al. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s312473 · Cited by 25
Ashford, M. T., Veitch, D. P., Neuhaus, J. M., Nosheny, R. L., Tosun, D., & Weiner, M. W. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12253 · Cited by 23
Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
Li, T.-R., Yang, Q. Z., Hu, X., & Han, Y. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210524153901 · Cited by 23
Giampietri, L., Belli, E., Beatino, M. F., Giannoni, S., Palermo, G., Campese, N., Tognoni, G., Siciliano, G., Ceravolo, R., Luca, C. D., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040796 · Cited by 22
Chen, Y.-H., Lin, R.-R., Huang, H.-F., Xue, Y., & Tao, Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.848180 · Cited by 25
Mumtaz, I., Ayaz, M. O., Khan, M. S., Manzoor, U., Ganayee, M. A., Bhat, A. Q., Dar, G. H., Alghamdi, B. S. A., Hashem, A. M., Dar, M. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977411 · Cited by 23
MRI-Based Screening of Preclinical Alzheimer’s Disease for Prevention Clinical Trials
Casamitjana, A., Petrone, P., Tucholka, A., Falcón, C., Skouras, S., Molinuevo, J. L., Vilaplana, V., Gispert, J. D., & Initiative, A. D. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180299 · Cited by 22
Westwood, S., Baird, A. L., Anand, S. N., Nevado‐Holgado, A. J., Kormilitzin, A., Shi, L., Hye, A., Ashton, N. J., Morgan, A. R., Bos, I., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190434 · Cited by 25
Shaw, L. M. J., Korecka, M., Figurski, M., Toledo, J. B., Irwin, D. J., Kang, J., & Trojanowski, J. Q. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.029587 · Cited by 21
Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 23
Plasma Biomarkers: Potent Screeners of Alzheimer’s Disease
Naveed, M., Mubeen, S., Khan, A., Ibrahim, S., & Meer, B. (2019) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317519848239 · Cited by 21
TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology
Jimenez‐Maggiora, G. A., Bruschi, S., Raman, R., Langford, O., Donohue, M., Rafii, M. S., Sperling, R. A., Cummings, J. L., & Aisen, P. S. S. (2020) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.48 · Cited by 21
Ramakrishnan, V., Friedrich, C. M., Witt, C. M., Sheehan, R., Pryor, M. M., Atwal, J. K., Wildsmith, K. R., Kudrycki, K., Lee, S., Mazer, N. A., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12876 · Cited by 21
de Souza, I. D., & Queiroz, M. E. C. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04631-9 · Cited by 20
Subramanian, N., Watson, B. E., Li, C., Moss, M. A., & Liu, C. (2023) · Sensors and Actuators Reports · doi:10.1016/j.snr.2023.100170 · Cited by 20
Baringer, S. L., Lukacher, A. S., Palsa, K., Kim, H., Lippmann, E. S., Spiegelman, V. S., Simpson, I. A., & Connor, J. R. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15954 · Cited by 21
Colmant, L., Boyer, E., Gérard, T., Sleegers, K., Lhommel, R., Ivanoiu, A., Lefèvre, P., Kienlen‐Campard, P., & Hanseeuw, B. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021173 · Cited by 21
Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20
Nolan, R. P., & Printz, M. A. (2024) · Clinical and Translational Science · doi:10.1111/cts.13788 · Cited by 18
Kobayashi, G., Hirata, K., Ono, M., Kasuga, K., & Takado, Y. (2026) · Frontiers in Dementia · doi:10.3389/frdem.2026.1736297 · Cited by 22
Cerebrospinal Fluid and Plasma Tau as a Biomarker for Brain Tauopathy
Shoji, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_29 · Cited by 20
Michno, W., Blennow, K., Zetterberg, H., & Brinkmalm, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15466 · Cited by 18
Tanaka, T., Chong, J. R., Nai, Y., Tan, C. H., Lim, C. Z. J., Zhang, Y., Stephenson, M. C., Hilal, S., Saridin, F. N., Gyanwali, B., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14704 · Cited by 19
Kreutzer, A. G., Parrocha, C. M. T., Haerianardakani, S., Guaglianone, G., Nguyen, J. T., Diab, M. N., Yong, W. H., Perez-Rosendahl, M. A., Head, E., & Nowick, J. S. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00592 · Cited by 20
Distinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms
Im, D., & Choi, T. S. (2024) · BMB Reports · doi:10.5483/bmbrep.2024-0044 · Cited by 19
Mei, X., Yang, M., Zhu, L., Zhou, Q., Li, X., Chen, Z., & Zou, C. (2020) · Behavioural Neurology · doi:10.1155/2020/1574816 · Cited by 18
Lu, W., Giudici, K. V., Rolland, Y., Guyonnet, S., Li, Y., Bateman, R. J., Barreto, P. D. S., & Vellas, B. J. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.60 · Cited by 17
Self-citationBiomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage
Li, T., Yang, Q. Z., Hu, X., & Han, Y. (2022) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 17
Yu, F., Han, S., Salisbury, D. L., Pruzin, J. J., Geda, Y. E., Caselli, R. J., & Li, D. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-022-01200-2 · Cited by 18
Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults
Lee, Y.-J., Lin, S., Peng, S., Lin, Y., Chen, T.-B., Wang, P.-N., & Cheng, I. H. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.15 · Cited by 18
Metadata
- Authors
- Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., Benzinger, T., Fagan, A. M., Patterson, B. W., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-07-19
- Volume
- 13
- Issue
- 8
- Pages
- 841-849
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC5567785
- OpenAlex
- W2736518852
- Cited by
- 585
- References
- 18
- Citations by year
- 2026: 44 · 2025: 44 · 2024: 74 · 2023: 65 · 2022: 84 · 2021: 85 · 2020: 70 · 2019: 66 · 2018: 47 · 2017: 2
- FWCI
- 37.40
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- MetLife Foundation
- AbbVie
- Amgen
- AstraZeneca
- Biogen
- Eisai
- Pfizer
- Sanofi
- Avid Radiopharmaceuticals
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, plasma amyloid-beta
- MeSH terms
- Aged, Amyloidosis, Chromatography, Liquid, Humans, Isotope Labeling, Kinetics, Peptide Fragments, Prospective Studies, ROC Curve, Mass Spectrometry, Biomarkers, Single-Blind Method, Amyloid beta-Peptides, Area Under Curve, Immunoprecipitation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
